61N1 Stock Overview
A vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
StageZero Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.018 |
| 52 Week High | CA$0.042 |
| 52 Week Low | CA$0.015 |
| Beta | 0.074 |
| 1 Month Change | 0% |
| 3 Month Change | -7.89% |
| 1 Year Change | -56.25% |
| 3 Year Change | -93.52% |
| 5 Year Change | -97.71% |
| Change since IPO | -98.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61N1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | -0.3% |
| 1Y | -56.3% | -14.3% | 7.0% |
Return vs Industry: 61N1 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 61N1 underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| 61N1 volatility | |
|---|---|
| 61N1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 61N1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 61N1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 40 | James Howard-Tripp | www.stagezerolifesciences.com |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.
StageZero Life Sciences Ltd. Fundamentals Summary
| 61N1 fundamental statistics | |
|---|---|
| Market cap | €3.34m |
| Earnings (TTM) | -€11.56m |
| Revenue (TTM) | €2.76m |
1.2x
P/S Ratio-0.3x
P/E RatioIs 61N1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61N1 income statement (TTM) | |
|---|---|
| Revenue | US$2.99m |
| Cost of Revenue | US$2.52m |
| Gross Profit | US$471.40k |
| Other Expenses | US$13.00m |
| Earnings | -US$12.53m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 15.75% |
| Net Profit Margin | -418.65% |
| Debt/Equity Ratio | -15.0% |
How did 61N1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/07 14:22 |
| End of Day Share Price | 2024/04/09 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
StageZero Life Sciences Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Chris Thompson | eResearch Corporation |
| Claude Camiré | Paradigm Capital, Inc. |